A new study from the VCU Massey Comprehensive Cancer Center in the United States highlights significant differences in how cancer survivors and their healthcare providers perceive and discuss medical cannabis. While both groups recognise the plant’s role in symptom management, the research uncovers notable gaps in awareness of potential risks among survivors and a lack of comfort among providers in initiating conversations about cannabis use.
The study, published in the Journal of Cancer Education, sheds light on the complex landscape of medical cannabis integration into oncology care. With increasing global access to cannabis for therapeutic purposes, understanding these divergent perspectives is crucial for fostering more effective patient-provider communication and developing informed clinical guidelines. The findings suggest a need for enhanced education for both patients and medical professionals to bridge existing knowledge and comfort gaps.
Understanding the Discrepancy in Perspectives
Conducted by a research team including Dr. Sunny Jung Kim, the study surveyed 395 cancer survivors and 62 cancer care providers. Dr. Kim, a researcher in the Cancer Prevention and Control program at VCU Massey and an associate professor at the VCU School of Public Health, noted that the research emerged from a broader initiative to explore alternatives to opioid-based pain management strategies. This context is vital, as many individuals, including cancer survivors, seek non-opioid options for symptom relief.
A key finding was the disparity in perceived risk awareness. Healthcare providers were substantially more likely to report an understanding of the potential risks associated with cannabis use, with 25% indicating awareness compared to only 8.4% of cancer survivors. This suggests that while survivors may be using cannabis, their knowledge of its potential downsides might be limited. Conversely, when it came to comfort in discussing cannabis, survivors expressed greater ease in bringing up the topic with their care team (68.5%) than providers did in initiating such conversations with patients (46.7%). This communication gap underscores a significant barrier to comprehensive patient care.
Providers also exhibited more negative attitudes towards recreational cannabis use than survivors. This difference in opinion could influence their willingness to engage in discussions about medical cannabis, even when used therapeutically. The study highlights that in many jurisdictions where medical cannabis is legal, such as Canada, Germany, or parts of Australia, healthcare professionals are increasingly confronted with patient inquiries about cannabis, making these communication dynamics globally relevant.
Impact of Cannabis Use on Survivor Well-being
The research delved into the characteristics and well-being of cannabis-using cancer survivors. Among those surveyed, survivors who reported using cannabis also indicated greater social well-being compared to non-users. However, this was coupled with lower reported physical and emotional well-being, a higher degree of mistrust in the healthcare system, and reduced overall engagement with healthcare services. These findings present a nuanced picture, suggesting that while cannabis may offer certain benefits, its use could also be correlated with other complex health and systemic issues.
Furthermore, cannabis-using survivors showed higher rates of smoking, vaping, anxiety, and depression when compared to those who did not use cannabis. Interestingly, there was no significant difference between the two groups regarding chronic pain, alcohol use, or sleep quality. The study also noted that the legality of cannabis in a survivor’s US state did not appear to influence their decision to use it, suggesting that personal perceived benefits often outweigh legal status in individual choices.
A particularly significant revelation was that over half (57.9%) of the cannabis-using survivors began their cannabis use before their cancer diagnosis. Dr. Kim drew a parallel to opioid use, suggesting that pre-existing patterns of use might increase the likelihood of dependency or chronic use problems. This distinction is clinically important, as it may identify a subgroup of patients who require more targeted attention and support in managing their cannabis use, much like patients with chemotherapy-induced neuropathy might seek specific symptom management strategies.
Bridging the Gaps: The Path Forward
The study’s findings underscore an urgent need for robust clinical evidence to solidify the understanding of cannabis’s benefits and risks in cancer care. Dr. Kim emphasised the importance of developing stronger clinical guidelines, which would provide healthcare providers with the confidence and framework needed to discuss and recommend medical cannabis appropriately. This aligns with broader calls for evidence-based practice in cannabis medicine across various international jurisdictions, including the UK, where medical cannabis patients often face stigma and a crisis of confidence in their care pathways.
Future research, according to Dr. Kim, should move beyond self-reported survey data. Longitudinal studies incorporating biomarkers and other objective measures are essential to establish causality and evaluate the actual outcomes of medical cannabis use, rather than relying solely on perceived effects. Such rigorous scientific investigation is critical for medical cannabis to gain wider acceptance and be more systematically integrated into conventional oncology protocols.
Ultimately, the study advocates for more open and candid conversations between cancer survivors and their healthcare providers. Enhancing patient-provider communication is paramount to ensuring that survivors can make informed decisions about medical cannabis as part of their comprehensive care plan. As medical cannabis research continues to evolve, similar to studies exploring THC and CBD combinations for conditions like dementia, clear communication remains the bedrock of effective, patient-centred treatment.
Frequently Asked Questions
What did the study on cancer survivors and medical cannabis find?
The study found that cancer survivors and their healthcare providers have differing views on medical cannabis, particularly regarding risk awareness and comfort in discussing its use. Providers were more aware of risks, while survivors were more comfortable initiating discussions.
Who conducted this research?
The study was conducted by researchers at the VCU Massey Comprehensive Cancer Center in the United States, with Dr. Sunny Jung Kim as the corresponding author.
What were the key differences in risk perception?
Healthcare providers were significantly more likely to be aware of potential cannabis risks (25%) compared to cancer survivors (8.4%).
How did communication comfort differ between groups?
Cancer survivors reported being more comfortable discussing cannabis with their care team (68.5%) than providers were in bringing up the topic with patients (46.7%).
Did prior cannabis use influence outcomes for survivors?
Yes, over half of cannabis-using survivors started before their cancer diagnosis. The study suggests this group may need more careful attention due to a potential inclination towards dependency, similar to patterns seen with opioid use.
What are the study’s recommendations for future care?
The study recommends stronger clinical evidence, standardised guidelines, more education for providers, and longitudinal research using objective measures to better integrate medical cannabis into cancer care and improve patient-provider communication.
This report is based on original reporting by Cannabishealthnews.co.uk.
